Research Analysts Issue Forecasts for PDSB FY2024 Earnings

PDS Biotechnology Co. (NASDAQ:PDSB) – Analysts at B. Riley reduced their FY2024 EPS estimates for shares of PDS Biotechnology in a research note issued to investors on Monday, November 25th. B. Riley analyst M. Mamtani now anticipates that the company will earn ($1.12) per share for the year, down from their prior forecast of ($1.06). B. Riley has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($1.18) per share. B. Riley also issued estimates for PDS Biotechnology’s Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.37) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($1.52) EPS and FY2028 earnings at ($1.77) EPS.

Other research analysts also recently issued reports about the company. StockNews.com downgraded PDS Biotechnology from a “hold” rating to a “sell” rating in a research note on Saturday, November 9th. HC Wainwright reissued a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research note on Friday, November 15th. Finally, Alliance Global Partners upgraded shares of PDS Biotechnology to a “strong-buy” rating in a research report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

PDS Biotechnology Stock Up 1.9 %

PDSB stock opened at $2.15 on Wednesday. The firm has a fifty day moving average price of $3.06 and a two-hundred day moving average price of $3.17. The company has a debt-to-equity ratio of 0.55, a current ratio of 2.84 and a quick ratio of 2.84. PDS Biotechnology has a 1-year low of $1.53 and a 1-year high of $6.68. The firm has a market cap of $80.43 million, a price-to-earnings ratio of -1.85 and a beta of 1.93.

Institutional Trading of PDS Biotechnology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Tempus Wealth Planning LLC acquired a new position in shares of PDS Biotechnology during the second quarter valued at approximately $55,000. Ground Swell Capital LLC bought a new position in PDS Biotechnology during the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of PDS Biotechnology during the 2nd quarter valued at $115,000. Squarepoint Ops LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth $120,000. Finally, Cubist Systematic Strategies LLC bought a new stake in shares of PDS Biotechnology in the 2nd quarter worth $146,000. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.